ClinicalTrials.gg

Skin Diseases, Infectious clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 45 studies for Skin Diseases, Infectious across more than 10 countries. 2 are recruiting or about to start. 16 of them are mainly about Skin Diseases, Infectious (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-20. Counting its 21 narrower conditions too, such as Hidradenitis Suppurativa: 1,666 studies, 245 open.

Status

Completed
35
Terminated
4
Status unknown
2
Not yet recruiting
2
Active, not recruiting
1
Withdrawn
1

Phase

Phase 3
12
Phase 2
12
Phase 4
8
Phase 1
2

Where

United States
18
Taiwan
2
Japan
2
Mexico
2
Canada
2
Argentina
2

Who develops what

Add Skin Diseases, Infectious to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 0 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
shingrixRecent, limitedPhase 4 trial recorded
Evidence
  • NCT07205796 · Shenzhen Shenxin Biotechnology Co., Ltd · Phase 2 · live · comparator · “Shingrix” · registered Sep 2025
GlaxoSmithKline88% of its industry studies11 study
LinezolidEarlier only
Evidence
  • NCT03716024 · Paratek Pharmaceuticals Inc · Phase 2 · comparator · “Linezolid” · registered Oct 2018
  • NCT01967225 · Bayer · Phase 3 · comparator · “Linezolid” · registered Oct 2013
  • NCT01128530 · AbbVie · Phase 2 · comparator · “linezolid” · registered May 2010
  • NCT00865280 · Paratek Pharmaceuticals Inc · Phase 3 · comparator · “linezolid” · registered Mar 2009
  • NCT00646958 · CorMedix Therapeutics · Phase 2 · comparator · “Linezolid” · registered Mar 2008
Pfizer78% of its industry studiesUS: off-patent, 16 generics marketed00 studies
VancomycinEarlier only
Evidence
  • NCT00430937 · Novartis · Phase 3 · comparator · “Vancomycin” · registered Feb 2007
  • NCT00228982 · Basilea Pharmaceutica · Phase 3 · comparator · “Vancomycin” · registered Sep 2005
  • NCT00210899 · Basilea Pharmaceutica · Phase 3 · comparator · “Vancomycin plus Ceftazidime” · registered Sep 2005
Pfizer27% of its industry studiesUS: off-patent, 32 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Skin Diseases, Infectious studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

0studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

Who these studies take

No Skin Diseases, Infectious study is recruiting now.

Across all 45 studies, recruiting or not: 33% stop at 75 or younger and 27% at 65; 33% take children; 2% are for women only and 4% for men only; 22% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 45 of 45. search them.